Tradestie Institutional Equity Comparison Engine

XBIO vs DRIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

XBIO Overall Edge

XBIO Captures Institutional Edge (2โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Xenetic Biosciences, Inc. (XBIO) driven by superior Growth & Margin, Momentum & Technical while DRIO counters with relative strength in Valuation. Fundamentally, XBIO trades at N/M Forward P/E with -81.0% operating margin (+12.0% YoY revenue) versus DRIO at 10.6x Forward P/E and -142.7% operating margin (+6.1% YoY). In options structure, XBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against DRIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner DRIO
XBIO N/M vs DRIO 10.6x Fwd P/E
Growth & Margin Winner XBIO
Op Margin -81.0% vs -142.7% ยท YoY +12.0% vs +6.1%
Momentum & Technical Winner XBIO
1Y -44.9% vs -90.0% ยท 52W Pos 4% vs 2%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
XBIO NASDAQ
Xenetic Biosciences, Inc.
Pharmaceutical Preparations
$1.40
-9.09% 1D
Market Cap $3.6M
1M Return -27.46%
1Y Return -44.88%
Forward P/E N/M
Unified AI Score
43.5 / 100 HOLD
Tech 25.0 Fund 56.0 Flow 50.0 Mom 55.0
DRIO NASDAQ
DarioHealth Corp. Common Stock
Surgical & Medical Instruments & Apparatus
$1.32
-8.33% 1D
Market Cap $16.3M
1M Return -61.29%
1Y Return -90.02%
Forward P/E 10.6x
Unified AI Score
42.2 / 100 HOLD
Tech 50.0 Fund 52.0 Flow 50.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: XBIO -44.88% DRIO -90.02% Spread: +45.69 pp (XBIO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
XBIO TTM Op. Margin: -81.0% DRIO TTM Op. Margin: -142.7%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XBIO vs DRIO. Trailing 12-month operating profitability (XBIO -81.0% vs DRIO -142.7%) and valuation multiples (XBIO N/M vs DRIO 10.6x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: XBIO (6) vs DRIO (4)
Institutional Metric XBIO DRIO Criterion Row Winner
Market Capitalization Scale $3.6M $16.3M Larger Scale DRIO
Trailing P/E Ratio Valuation N/M 10.6x Lower Multiple DRIO
Forward P/E Ratio Valuation N/M 10.6x Lower Multiple DRIO
Revenue Growth (YoY) Growth +12.0% +6.1% Higher Growth XBIO
Operating Margin (TTM) Profitability -81.0% -142.7% Higher Margin XBIO
Net Profit Margin Profitability -75.9% -159.9% Higher Margin XBIO
Return on Equity (ROE) Capital Efficiency -47.0% -46.6% Higher ROE DRIO
52-Week Range Position Momentum 4% ($1โ€“$5) 2% ($1โ€“$15) Stronger Trend XBIO
Beta / 30D Volatility Risk Regime 1.40ฮฒ ยท 99% Vol 0.45ฮฒ ยท 182% Vol Lower Realized Risk XBIO
Unified Institutional Score Composite Signal 43.5 / 100 (HOLD) 42.2 / 100 (HOLD) Higher Composite XBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full XBIO vs DRIO Buy Guide
XBIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live XBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DRIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live DRIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither XBIO nor DRIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.